LEADER 01552nam  2200397   450 
001 9910707486803321
005 20160811083738.0
035   $a(CKB)5470000002464657
035   $a(OCoLC)956500470
035   $a(OCoLC)995470000002464657
035   $a(EXLCZ)995470000002464657
100   $a20160811d2016      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aFDA is issuing more postmarketing requirements, but challenges with oversight persist
210  1$a[Washington, D.C.] :$cDepartment of Health and Human Services, Office of Inspector General,$d2016.
215   $a1 online resource (26 pages) $cillustrations
300   $aTitle from title screen (viewed Aug 9, 2016).
300   $a"July 2016."
300   $a"OEI-01-14-00390."
320   $aIncludes bibliographical references.
517 3 $aFood and Drug Administration is issuing more postmarketing requirements, but challenges with oversight persist
517 1 $aFDA is issuing more postmarketing requirements, but challenges with oversight persist
606   $aDrugs$zUnited States$xTesting$xManagement
606   $aClinical trials$xGovernment policy$zUnited States
615  0$aDrugs$xTesting$xManagement.
615  0$aClinical trials$xGovernment policy
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707486803321
996   $aFDA is issuing more postmarketing requirements, but challenges with oversight persist$93304909
997   $aUNINA